Introduction: Exploratory assessment of gastric and small bowel contractility response to the motilin receptor agonist camicinal (C), using the wireless motility capsule (WMC). Methods: Patients with diabetes with gastroparesis (confirmed by 13 C oral breath test) with at least moderate symptoms were enrolled in a double blind randomized study of placebo, 10, 50, or 125 mg doses of C daily for 28 days. The study design, primary efficacy, and safety results of this study have been previously reported (Barton ME, DDW 2014). The WMC was given 3 times over the course of the 4-week study: at baseline (day 0) prior to treatment, day 1 of treatment, and day 28 of treatment. The frequency of contractions (CT), area under the pressure curve (AUC), and motility index (MI) were analyzed in the 1-hour period prior to (antral [A] window) and post WMC gastric emptying (duodenal [D] window) with GIMS Data Viewer 3.0. Subjects whose WMC data included >70% of available pressure samples in A and D analyses windows and for whom a paired t test analyses between day 0 and 1, day 0 and 28, and day 1 and 28 was appropriate were evaluated. The 3 dosage groups were combined in 1 data set for analyses. Results: Seventy-nine subjects were in the study. The most common drug-related AEs were headache, UTI, and GI symptoms, similar in frequency across treatment groups. There were no study withdrawals due to AEs, nor any drug-related serious adverse events. A paired t test analysis combining all treatment levels except placebo between day 0 and 1 included 23 subjects in the A window and 28 subjects in the D window. In A window, significant increases were observed in mean CT from 64 to 106 CT/hr (p=0.02), AUC from 4,008 to 6485 mmHg/sec (p=0.02), and MI from 11.17 to 12.21 in (CT x Sum Amp+1) (p=0.02). The corresponding analyses for differences in mean pressure parameters between day 0 and day 28 included 27 and 33 subjects in the A and D windows, respectively, and showed no significant difference in pressure parameters on day 28 (p>0.3). Mean values for CT, AUC, and MI increased between day 1 and 28 for the 28 and 31 subjects in the A and D windows, respectively (p>0.09). When analyzing the placebo group only, there were no significant changes in motility parameters for either A or D windows on day 1 or day 28 compared to day 0. No significant changes in the small bowel pressure profiles were observed. Conclusion: Data suggests gastric pressure profiles prior to gastric emptying improve in diabetic gastroparesis patients following motilin receptor agonist treatment, whereas small bowel motility parameters following gastric emptying are not affected significantly. Disclosure - George Dukes - Employee, GSK; Matthew Barton - Employee, GSK; Kenneth Barshop - none; Braden Kuo - Consultant, GSK; Jack Semler - Consultant, GSK, Given Imaging. This research was supported by an industry grant from GSK.